Liquidia (NASDAQ:LQDA – Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Liquidia to post earnings of $0.96 per share and revenue of $214.18 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company’s revenue was up 1842.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.49) EPS. On average, analysts expect Liquidia to post $2.05 EPS for the current fiscal year and $2.13 EPS for the next fiscal year.
Liquidia Price Performance
NASDAQ:LQDA opened at $45.06 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia has a one year low of $22.21 and a one year high of $93.61. The company has a fifty day moving average price of $52.99 and a 200 day moving average price of $54.30. The stock has a market cap of $4.03 billion, a P/E ratio of 32.89, a PEG ratio of 0.39 and a beta of 0.61.
Insider Buying and Selling
In other news, CEO Roger Jeffs sold 32,744 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the sale, the chief executive officer owned 1,125,848 shares of the company’s stock, valued at $32,064,151.04. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Stephen M. Bloch sold 235,477 shares of Liquidia stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.13, for a total value of $6,388,491.01. The SEC filing for this sale provides additional information. Insiders have sold 566,579 shares of company stock worth $25,746,120 over the last ninety days. Insiders own 25.60% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on LQDA shares. Piper Sandler set a $129.00 price objective on Liquidia in a research report on Friday, July 24th. BTIG Research upgraded shares of Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price target on the stock in a research report on Wednesday, October 14th. Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. Wedbush set a $58.00 price target on Liquidia in a report on Friday, October 2nd. Finally, Bank of America boosted their target price on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $72.85.
Read Our Latest Stock Analysis on LQDA
Liquidia Company Profile
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.
Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.
Read More
- Five stocks we like better than Liquidia
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
